Scarica l'app Stockscreener
1.47
38.68%
0.41
Precedente Chiudi:
$1.06
Aprire:
$1.425
Volume 24 ore:
166.26M
Relative Volume:
26.88
Capitalizzazione di mercato:
$10.94M
Reddito:
-
Utile/perdita netta:
$-16.28M
Rapporto P/E:
-0.1057
EPS:
-13.91
Flusso di cassa netto:
$-13.75M
1 W Prestazione:
+402.91%
1M Prestazione:
+103.60%
6M Prestazione:
+64.14%
1 anno Prestazione:
-49.31%
Intervallo 1D:
$1.34
$2.06
Intervallo di 1 settimana:
$0.32
$2.06
Portata 52W:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Nome
Pasithea Therapeutics Corp
Settore
Industria
Telefono
(702) 514-4174
Indirizzo
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Confronta KTTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.47 | 7.89M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Penny Stocks To Follow NowNovember 28th - MarketBeat
Pasithea’s Stock Surge: Is It Time to Invest? - StocksToTrade
Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise - Nasdaq
Pasithea Therapeutics (KTTAW) Stock: Sees 56% Surge After $60M Public Offering for Growth - parameter.io
Biotech Minors Make Major Moves On FDA News And Stock Sales - Finimize
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Did KTTA Stock Soar A Whopping 48% Today? - Asianet Newsable
Pasithea Therapeutics prices 80M shares at 75c in public offering - TipRanks
Why Did KTTA Stock Soar A Whopping 43% Today? - Stocktwits
Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up - Nasdaq
Pasithea Therapeutics Prices $60 Million Public Offering - MarketScreener
Pasithea Therapeutics Corp. Completes Public Offering to Extend Cash Runway through First Half of 2028 - Quiver Quantitative
Pasithea Therapeutics (Nasdaq: KTTA) prices 80M shares at $0.75, extending cash runway through 1H 2028 - Stock Titan
Pasithea Surprises: Will the Surge Continue? - timothysykes.com
Best Penny Stocks To Follow Today – November 26th - Defense World
Penny Stocks To Follow TodayNovember 27th - MarketBeat
3 Penny Stocks to Watch Now, 11/27/25 - TipRanks
Pasithea Therapeutics Stock Rockets To Best Day In 4 Years On Massive Share Offering Amid ALS Drug Momentum - Stocktwits
Pasithea’s Promising Trials: A Clear Path? - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today - inkl
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004 - TipRanks
ALS Association awards $1 million to study Pasithea’s PAS-004 in ALS - Investing.com Nigeria
Pasithea Therapeutics announces $1M award by ALS Association - TipRanks
Pasithea Therapeutics (NASDAQ: KTTA) PAS-004 Phase I ALS Study to Enroll 12 Patients - Stock Titan
Pasithea Therapeutics Corp.Common Stock (Nasdaq:KTTA) Stock Quote - Markets Financial Content
Pasithea reports positive safety data from PAS-004 cancer trial By Investing.com - Investing.com Nigeria
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics announces completion of cohort 7 in ongoing phase 1 trial of PAS-004 - MarketScreener
Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004 - TradingView
Pasithea reports positive safety data from PAS-004 cancer trial - Investing.com
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - MarketScreener
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell? - Defense World
Pasithea reports positive PK data for PAS-004 tablet formulation By Investing.com - Investing.com Nigeria
Pasithea Therapeutics says positive PAS-004 tablet pharmacokinetic data in ongoing Phase 1/1b trial in adult NF1 patients - MarketScreener
Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients - TradingView
Pasithea says tablet PK exposure increases proprtionally with dose increase - TipRanks
Pasithea Therapeutics' PAS-004 Shows Favorable Pharmacokinetic Properties in Tablets in Phase 1 Trial - MarketScreener
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Investing News Network
Pasithea reports positive PK data for PAS-004 tablet formulation - Investing.com
Pasithea Therapeutics Announces Positive PAS-004 Tablet - GlobeNewswire
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Sahm
Pasithea Therapeutics Corp. (KTTA) -23.4% in Normal Trading: Despite Positive Phase 1 Data - Stocks Telegraph
Why Is Pasithea Therapeutics Stock (KTTA) Down Today? - TipRanks
Pasithea reports positive interim data for MEK inhibitor in cancer trial - Investing.com Canada
Real time scanner hits for Pasithea Therapeutics Corp. Equity Warrant explainedMarket Growth Summary & Technical Pattern Based Signals - newser.com
Pasithea Therapeutics announces positive phase 1 data including partial response - MarketScreener
Pasithea Therapeutics stock plunges after Phase 1 interim data release By Investing.com - Investing.com Nigeria
Pasithea Therapeutics stock plunges after Phase 1 interim data release - Investing.com
Pasithea Therapeutics Corp Azioni (KTTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pasithea Therapeutics Corp Azioni (KTTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
0.45%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):